Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.20.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 31 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Operating Activities:      
Net loss $ (3,320) $ (5,904)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization [note 3] 61 65  
Stock-based compensation [note 6 [c] and note 6 [d]] 302 290  
Changes in operating assets and liabilities:      
Amounts receivable 8    
Prepaid expenses and other assets (190) 88  
Accounts payable (675) 550  
Accrued liabilities other (130) (199)  
Accrued clinical liabilities 184 887  
Accrued compensation (697) (680)  
Lease obligation [note 7] (4) 14  
Net cash used in operating activities (4,461) (4,889)  
Financing Activities:      
Net cash used in financing activities (47)    
Investing Activities:      
Purchase of property and equipment (2) (54)  
Purchase of investments   (20)  
Proceeds from maturities of investments   2,764  
Net cash provided by (used in) investing activities (2) 2,690  
Effect of exchange rate changes on cash 2 4  
Net increase (decrease) in cash, cash equivalents and restricted cash (4,508) (2,195)  
Cash, cash equivalents and restricted cash at beginning of the period 16,714 9,565  
Cash, cash equivalents and restricted cash at end of the period 12,206 $ 7,370 $ 12,206
LPC [Member]      
Financing Activities:      
Costs relating to registered direct offering and purchase agreement     $ (500)
LPC [Member] | Purchase Agreement [Member]      
Financing Activities:      
Costs relating to registered direct offering and purchase agreement (13)    
December 2019 Registered Direct Offering [Member]      
Financing Activities:      
Costs relating to registered direct offering and purchase agreement $ (34)